Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease
Status:
Terminated
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This is an open label study of isotretinoin, a medication which is FDA approved for treatment
of other conditions to determine initial safety in Alzheimer's disease.